These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3500719)

  • 1. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.
    Fonne-Pfister R; Bargetzi MJ; Meyer UA
    Biochem Biophys Res Commun; 1987 Nov; 148(3):1144-50. PubMed ID: 3500719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
    Prueksaritanont T; Dwyer LM; Cribb AE
    Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
    Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
    J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
    Zanger UM; Vilbois F; Hardwick JP; Meyer UA
    Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the interactions of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) with the cytochrome P-450 enzyme system--clues to a possible aetiological factor in Parkinson's disease.
    Shahi GS; Moochhala SM; Lee EJ; Das NP
    Ann Acad Med Singap; 1989 Jan; 18(1):93-7. PubMed ID: 2785364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus).
    Uehara S; Uno Y; Inoue T; Murayama N; Shimizu M; Sasaki E; Yamazaki H
    Drug Metab Dispos; 2015 May; 43(5):735-42. PubMed ID: 25735838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
    Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
    Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
    Leemann T; Bonnabry P; Dayer P
    Life Sci; 1994; 54(14):951-6. PubMed ID: 8139385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes.
    Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M
    FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P4502D and -2C enzymes catalyze the oxidative N-demethylation of the parkinsonism-inducing substance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rat liver microsomes.
    Narimatsu S; Tachibana M; Masubuchi Y; Suzuki T
    Chem Res Toxicol; 1996; 9(1):93-8. PubMed ID: 8924622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
    Boobis AR; Murray S; Hampden CE; Davies DS
    Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors.
    Boobis AR; Seddon CE; Davies DS
    Biochem Pharmacol; 1986 Sep; 35(17):2961-5. PubMed ID: 3741485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.
    Larrey D; Distlerath LM; Dannan GA; Wilkinson GR; Guengerich FP
    Biochemistry; 1984 Jun; 23(12):2787-95. PubMed ID: 6432035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.
    Masimirembwa CM; Hasler JA; Johansson I
    Eur J Clin Pharmacol; 1995; 48(1):35-8. PubMed ID: 7621845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
    Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
    Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depression of the hepatic cytochrome P-450 monooxygenase system by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Shahi GS; Moochhala SM; Das NP
    Pharmacol Toxicol; 1989 Jan; 64(1):107-10. PubMed ID: 2787911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
    Haefeli WE; Bargetzi MJ; Follath F; Meyer UA
    J Cardiovasc Pharmacol; 1990 May; 15(5):776-9. PubMed ID: 1692938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes.
    Masubuchi Y; Iwasa T; Hosokawa S; Suzuki T; Horie T; Imaoka S; Funae Y; Narimatsu S
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1435-41. PubMed ID: 9316857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.